Navigating Customs Compliance for Double-Blind Clinical Trials in Switzerland

During a shipping timeline, from packing to customs clearance to final delivery, there is a real risk of a double-blind study’s drug classification being exposed. Because of the complex documentation required for shipping IMPs (Investigational Medicinal Products), sponsors and CROs face a real risk that the effectiveness of the clinical trial will be compromised. Exposure to the double-blind pharmaceutical classification causes a significant cost burden for the sponsor. If a program manager or blinded pharmacist is accidentally exposed, the sponsor could lose the patient to the study, the site, or even the whole country as a trial location.

An IOR safeguards a double-blind study because of its speciality in the documentation required for IMP shipments. An IOR acts as a middleman and removes the blinded participants from the steps where exposure is a risk. At all levels of communication with the sponsors or CRO, the IOR ensures that shipment details are not exposed to a blinded point of contact.

If an IOR handles the delivery, they ensure a blind contact won’t receive exposure through shipment notifications.

A general freight forwarder moves goods and will contact whoever is listed on the documentation, with the risk of slip-ups that could expose drug classification details. An IOR provides additional documentation that secures a shipment, removing it further from a blinding risk.

Switzerland has long been a global hotspot for pharmaceutical research, with advanced infrastructure, making it one of the most rewarding destinations for trials. With some areas aligning with EU standards, there is still an independent import and export framework, as it falls outside the union.

Despite Swissmedic’s strict compliance procedures, an additional step at customs complicates clinical shipment timelines. Before a shipment is allowed to ship to site, Swissmedic requires it to pass through the qualifying release party’s facilities, where a quality check must be performed. Each batch requires separate documentation, and the shipment review is completed in detail. This causes headaches for sponsors and CROs, as documentation may be sensitive and, in this case, could raise concerns about double-blind shipments.

If a shipment lists the IOR as the qualifying release party, it must first go to their facilities, and a quality check will be conducted to ensure that all documentation supports the shipment.

With TecEx Medical and our highly experienced in-country team, we can efficiently complete your shipment’s quality check. This includes ensuring that all documentation is aligned, that the physical cargo complies with double-blind standards, and that temperature controls remain in place. Our procedure allows your shipment to move to site as quickly and efficiently as possible.

Double-blind studies are considered the gold standard in clinical research for their enhanced credibility. In a double-blind clinical trial, neither the patient nor the treating persons know if the drug is the IMP, placebo, or a comparative drug. Similarly to how a patient could report bias if the classification of the drug was known, so also can a trial reporter or data analyst interpret a biased hypothesis.

Acting as an IOR, TecEx Medical specializes in shipping pharmaceuticals whilst complying with customs regulations and drawing on medical expertise to protect shipments from complications.

To ensure compliant shipping and protect your cargo from external complications, TecEx Medical has the expertise required for each shipment. With our constant communication channels, we know where your shipment is at all times, so we can prevent delays at customs.

Partnering with TecEx Medical, Sponsors and CRO’S can navigate each market’s specific compliance and import requirements. Our deep understanding of Swiss regulations has enabled us to streamline your double-blind pharmaceutical site as quickly as possible.